JBSS Stock Analysis: John Sanfilippo & Son | NASDAQ
Packaged Foods | NASDAQ, USA | Market Cap: 796m USD | 12M Return: 12.9% | US8004221078 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 8.13M
EPS Trend: 72.6%
Qual. Beats: -1
Rev. Trend: 94.5%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS) is a U.S.-based processor and distributor of tree nuts and peanuts, operating primarily through its subsidiary JBSS Ventures, LLC. The company sells raw and processed nuts (almonds, pecans, peanuts, walnuts, cashews, macadamia nuts, pistachios, pine nuts, and filberts) along with a broader portfolio that includes granola and nutrition bars, peanut butter, salad toppings, dried fruit, snack mixes, sunflower kernels, candy, corn and chickpea snacks, sesame sticks, and ice cream and yogurt toppings. It also runs a retail store.
The company markets its products under the Fisher, Orchard Valley Harvest, Squirrel Brand, and Southern Style Nuts brands, and also produces private-label items for other retailers. Its customer base spans retailers, wholesalers, and commercial ingredient and contract packaging clients, reached through a network of independent brokers, distributors, and suppliers. Founded in 1922 and headquartered in Elgin, Illinois, JBSS sits within the Consumer Staples sector (Packaged Foods & Meats sub-industry), a category characterized by stable demand and significant private-label penetration, both of which shape the companys contract packaging and co-manufacturing exposure.
- Almond and walnut input costs pressure gross margins
- Branded Fisher snacks gain retail shelf space
- Private label contract packaging drives volume growth
| Net Income: 61.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 8.80 > 1.0 |
| NWC/Revenue: 15.43% < 20% (prev 17.19%; Δ -1.77% < -1%) |
| CFO/TA 0.19 > 3% & CFO 123.8m > Net Income 61.9m |
| Net Debt (128.8m) to EBITDA (118.7m): 1.09 < 3 |
| Current Ratio: 2.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (11.8m) vs 12m ago 0.36% < -2% |
| Gross Margin: 17.96% > 18% (prev 18.38%; Δ -0.41% > 0.5%) |
| Asset Turnover: 187.2% > 50% (prev 185.3%; Δ 1.90% > 0%) |
| Interest Coverage Ratio: 35.16 > 6 (EBIT TTM 85.4m / Interest Expense TTM 2.43m) |
| A: 0.28 (Total Current Assets 349.3m - Total Current Liabilities 167.9m) / Total Assets 658.6m |
| B: 0.36 (Retained Earnings 236.7m / Total Assets 658.6m) |
| C: 0.14 (EBIT TTM 85.4m / Avg Total Assets 628.1m) |
| D: 1.36 (Book Value of Equity 379.9m / Total Liabilities 278.6m) |
| Altman-Z'' = 5.32 = AAA |
| DSRI: 1.04 (Receivables 84.5m/76.8m, Revenue 1.18b/1.11b) |
| GMI: 1.02 (GM 18.38% / 17.96%) |
| AQI: 0.71 (AQ_t 0.09 / AQ_t-1 0.12) |
| SGI: 1.06 (Revenue 1.18b / 1.11b) |
| TATA: -0.09 (NI 61.9m - CFO 123.8m) / TA 658.6m) |
| Beneish M = -3.12 (Cap -4..+1) = AA |
As of October 12, 2026, the stock is trading at USD 67.00 with a total of 132,510 shares traded. Over the past week, the price has changed by -2.22%, over one month by -5.15%, over three months by -21.74% and over the past year by +12.91%.
Current recommended Stop Loss: 64.70 (which is 3.4% or 1.3 ATR below the current price).
John Sanfilippo & Son has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy JBSS.
- StrongBuy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 100 | 49.3% |
P/E Trailing = 12.9335
P/E Forward = 10.5485
P/S = 0.6766
P/B = 2.0833
P/EG = 1.5178
Revenue TTM = 1.18b USD
EBIT TTM = 85.4m USD
EBITDA TTM = 118.7m USD
Long Term Debt = 43.6m USD (from longTermDebt, last quarter)
Short Term Debt = 45.1m USD (from shortTermDebt, last quarter)
Debt = 130.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 20.6m
Net Debt = 128.8m USD (calculated: Debt 130.0m - CCE 1.15m)
Enterprise Value = 924.4m USD (795.5m + Debt 130.0m - CCE 1.15m)
Interest Coverage Ratio = 35.16 (Ebit TTM 85.4m / Interest Expense TTM 2.43m)
EV/FCF = 25.86x (Enterprise Value 924.4m / FCF TTM 35.7m)
FCF Yield = 3.87% (FCF TTM 35.7m / Enterprise Value 924.4m)
FCF Margin = 3.04% (FCF TTM 35.7m / Revenue TTM 1.18b)
Net Margin = 5.27% (Net Income TTM 61.9m / Revenue TTM 1.18b)
Gross Margin = 17.96% ((Revenue TTM 1.18b - Cost of Revenue TTM 964.5m) / Revenue TTM)
Gross Margin QoQ = 15.74% (prev 19.08%)
Tobins Q-Ratio = 1.40 (Enterprise Value 924.4m / Total Assets 658.6m)
Interest Expense / Debt = 1.87% (Interest Expense 2.43m / Debt 130.0m)
Taxrate = 25.36% (21.0m / 83.0m)
NOPAT = 63.7m (EBIT 85.4m * (1 - 25.36%))
Current Ratio = 2.08 (Total Current Assets 349.3m / Total Current Liabilities 167.9m)
Debt / Equity = 0.34 (Debt 130.0m / totalStockholderEquity, last quarter 379.9m)
Debt / EBITDA = 1.09 (Net Debt 128.8m / EBITDA 118.7m)
Debt / FCF = 3.60 (Net Debt 128.8m / FCF TTM 35.7m)
Total Stockholder Equity = 375.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 9.86% (Net Income 61.9m / Total Assets 658.6m)
RoE = 16.51% (Net Income TTM 61.9m / Total Stockholder Equity 375.1m)
RoCE = 20.40% (EBIT 85.4m / Capital Employed (Equity 375.1m + L.T.Debt 43.6m))
RoIC = 11.92% (NOPAT 63.7m / Invested Capital 534.6m)
WACC = 5.10% (E(795.5m)/V(925.5m) * Re(5.71%) + D(130.0m)/V(925.5m) * Rd(1.87%) * (1-Tc(0.25)))
Discount Rate = 5.71% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 88.37 | Cagr: 0.30%
[DCF] Terminal Value 75.44% ; FCFF base≈35.7m ; Y1≈35.9m ; Y5≈38.0m
[DCF] Fair Price = 50.85 (EV 591.4m - Net Debt 128.8m = Equity 462.6m / Shares 9.10m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: 72.61 | EPS CAGR: 12.03% | SUE: -1.17 | # QB: -1
Revenue Correlation: 94.49 | Revenue CAGR: 6.30% | SUE: 0.01 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.53 | Chg30d=-11.06% | Revisions=+25% | Analysts=2
EPS next Quarter (2026-12-31): EPS=1.34 | Chg30d=-10.98% | Revisions=+0% | Analysts=2
EPS current Year (2027-06-30): EPS=5.36 | Chg30d=-7.45% | Revisions=-25% | GrowthEPS=+1.8% | GrowthRev=+2.0%
EPS next Year (2028-06-30): EPS=5.41 | Chg30d=-4.59% | Revisions=+0% | GrowthEPS=+1.0% | GrowthRev=+3.1%
[Analyst] Revisions Ratio: +0% (up=1, down=1)